000156657 001__ 156657
000156657 005__ 20251017144601.0
000156657 0247_ $$2doi$$a10.1111/bjh.16917
000156657 0248_ $$2sideral$$a118932
000156657 037__ $$aART-2020-118932
000156657 041__ $$aeng
000156657 100__ $$aPrieto-Torres, L
000156657 245__ $$aTwo independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement
000156657 260__ $$c2020
000156657 5060_ $$aAccess copy available to the general public$$fUnrestricted
000156657 5203_ $$aSeveral studies have provided evidence of the presence of lymphoma stem cells by showing the apparent transmission of premalignant lymphoid cells in allogeneic bone marrow transplantation, where the donor and recipient develop the same lymphoid disease.1-6 The lymphoid neoplasms do not develop at the same time, and in some cases, a different immunoglobulin heavy chain (IgH) rearrangement occurs in the two tumours. These data support the theory of a common lymphoma precursor cell (CPC) and make it less likely that it is due to a circulating donor tumour cell. Recently, Hattori et al.7 published genetic evidence of CPC in primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), suggesting that intra- and extra-CNS tumours in the same patient are derived from CPC with myeloid differentiation factor 88 (MYD88) L265P gene mutations, which arise before or after the IgH rearrangement. They suggested that CPC maps to different positions during B-lineage differentiation. The position after IgH rearrangement and even after hypermutation at the variable region could explain the appearance of clonally related lymphomas, whereas the emergence of CPC before IgH rearrangement might account for the presence of clonally unrelated B-cell lymphomas in the same patient because divergence may occur before the Variable-Diversity-Junctional (VDJ) rearrangements.
000156657 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-01294$$9info:eu-repo/grantAgreement/ES/ISCIII/PI17-02172$$9info:eu-repo/grantAgreement/ES/MINECO-RTICC-ISCIII-CIBERONC/PIE15-0081$$9info:eu-repo/grantAgreement/ES/MINECO-RTICC-ISCIII-CIBERONC/RD06-0020-0107-RD012-0036-0060$$9info:eu-repo/grantAgreement/ES/MINECO-RTICC-ISCIII-CIBERONC/SAF2013-47416-R
000156657 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es
000156657 590__ $$a6.998$$b2020
000156657 591__ $$aHEMATOLOGY$$b12 / 76 = 0.158$$c2020$$dQ1$$eT1
000156657 592__ $$a1.907$$b2020
000156657 593__ $$aHematology$$c2020$$dQ1
000156657 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000156657 700__ $$aTrascasa, A
000156657 700__ $$aManso, R
000156657 700__ $$aMachan, S
000156657 700__ $$aCieza-Diaz, D
000156657 700__ $$aOlmedilla, G
000156657 700__ $$0(orcid)0000-0003-2078-8205$$aGarcia-Garcia, M$$uUniversidad de Zaragoza
000156657 700__ $$0(orcid)0000-0001-8789-6783$$aAra-Martin, M$$uUniversidad de Zaragoza
000156657 700__ $$aRequena, L
000156657 700__ $$aPiris, MA
000156657 700__ $$aRodriguez-Pinilla, SM
000156657 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000156657 7102_ $$11013$$2020$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Anatomía Patológica
000156657 773__ $$g190, 6 (2020), e352-e356$$pBr. j. haematol.$$tBRITISH JOURNAL OF HAEMATOLOGY$$x0007-1048
000156657 8564_ $$s2932099$$uhttps://zaguan.unizar.es/record/156657/files/texto_completo.pdf$$yVersión publicada
000156657 8564_ $$s2538991$$uhttps://zaguan.unizar.es/record/156657/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000156657 909CO $$ooai:zaguan.unizar.es:156657$$particulos$$pdriver
000156657 951__ $$a2025-10-17-14:14:19
000156657 980__ $$aARTICLE